Prove the
next indication.
Accelerate label expansion by generating rigorous real-world evidence for new indications and sub-populations.
Evidence beyond the trial.
A successful pivotal trial is just the beginning. The real-world data holds the key to new indications, expanded patient populations, and revised dosage guidelines.
Frekil allows medical affairs and clinical development teams to instantly query massive real-world datasets, validating hypotheses for label expansion. Generate foundational evidence for new indications without initiating costly, multi-year prospective studies.
New Indications
Identify off-label usage patterns and validate efficacy in novel disease states.
Pediatric & Geriatric
Generate safety and efficacy profiles for populations excluded from original pivotal trials.
Dosage Optimization
Analyze real-world dosing regimens and their correlation with clinical outcomes.
Subgroup Analysis
Isolate specific biomarkers or comorbidities where your asset shows exceptional performance.